Section: Bilateral Contracts and Grants with Industry

Bilateral Contracts with Industry

Implication in research for the development of vaccine has lead to a direct contracts with industry such as withs Iliad Biotechnologies. This contract had been signed for the BPZE-1 pertussis vaccine trial. This study evaluates the safety and immunogenicity of a higher dose formulation of a new live attenuated vaccine, BPZE1, intended to prevent Bordetella pertussis nasopharyngeal colonization and pertussis disease, and investigates whether higher doses of BPZE1 induce the live vaccine to colonize subjects' nasopharynx. The study is a Phase Ib (high dose), single centre, dose-escalating, placebo-controlled study of the live attenuated B. pertussis strain BPZE1 given as a single intranasal dose to healthy adult volunteer. This contrat is part of the EUCLID platform (via the CIC 1401) in which Laura Richert and Rodolphe Thiébaut are involved.